Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.
Article Details
- CitationCopy to clipboard
Patel UJ, Caulfield S
Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.
J Adv Pract Oncol. 2019 Jul;10(5):501-507. doi: 10.6004/jadpro.2019.10.5.8. Epub 2019 Jul 1.
- PubMed ID
- 33457063 [ View in PubMed]
- Abstract
Prostate cancer is the fourth leading cause of cancer in the United States. Treatment of this oncologic disease involves a variety of different modalities including surgery, radiation, and systemic therapy. Systemic therapy is used for locally advanced and metastatic disease, and primarily involves hormonal blockade as a mechanism of disease control. Apalutamide is a nonsteroidal androgen receptor inhibitor that binds directly to the androgen receptor ligand binding-domain to prevent androgen receptor translocation. This agent is used in combination with gonadotropin-releasing hormone antagonists to shut down the production of testosterone through the reproductive system. It is the first drug to receive U.S. Food & Drug Administration approval for the treatment of nonmetastatic, castration-resistant prostate cancer. This article reviews the pharmacology of apalutamide along with its current place in therapy and management of associated adverse events.
DrugBank Data that Cites this Article
- Drug Carriers
Drug Carrier Kind Organism Pharmacological Action Actions Apalutamide Serum albumin Protein Humans NoBinderDetails